

# The role of transcription factors in atrial fibrillation

Mengchen Zhou<sup>1,2</sup>, Yuhua Liao<sup>2</sup>, Xin Tu<sup>1</sup>

<sup>1</sup>Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-X Institute, Huazhong University of Science and Technology, Wuhan 430074, China; <sup>2</sup>Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430000, China

Correspondence to: Xin Tu. Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-X Institute, Huazhong University of Science and Technology, Wuhan 430074, China. Email: xtu@hust.edu.cn.

**Abstract:** Atrial fibrillation (AF) is a complex disease that results from genetic and environmental factors and their interactions. In recent years, genome-wide association studies (GWAS) and family-based linkage analysis have found amounts of genetic variants associated with AF. Some of them lie in coding sequences and thus mediate the encoded proteins, some in non-coding regions and influence the expression of adjacent genes. These variants exert influence on the development of cardiovascular system and normal cardiac electrical activity in different levels, and eventually contribute to the occurrence of AF. Among these affected genes, as a crucial means of transcriptional regulation, several transcription factors play important roles in the pathogenesis of AF. In this review, we will focus on the potential role of *PITX2*, *PRRX1*, *ZHFX3*, *TBX5*, and *NKX2.5* in AF.

**Keywords:** Atrial fibrillation (AF); transcription factors; *PITX2*; *PRRX1*; *ZHFX3*; *TBX5*; *NKX2.5*

Submitted Mar 25, 2014. Accepted for publication Dec 09, 2014.

doi: 10.3978/j.issn.2072-1439.2015.01.21

View this article at: <http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.21>

Atrial fibrillation (AF), the most common cardiac arrhythmia, is characterized by absence of P waves and irregular R-R intervals (1). AF has an estimated prevalence rate of 0.4% to 1.0% in the general population, and there are approximately 10 million AF patients in China and the number of AF patients is estimated to reach 15.9 million in the United States by 2050 (2-5). AF is a complex disease that results from genetic and environmental factors and their interactions (6,7). Framingham Heart Study has revealed that familiar history plays an important role in AF [OR =1.40, 95% confidence interval (CI): 1.13-1.74, with P value =0.02] and suggested that genetic variations may play important roles in the pathogenesis of AF (8).

Using linkage analysis and positional cloning approach, several genetic loci, such as *KCNQ1*, *KCNE2*, *KCNJ2*, *KCNA5*, *KCNH2*, *SCN5A*, *SCN3B*, *NPPA* and *NUP155*, have been found for familiar or monogenic AF and casual genes, including *KCNQ1*, *KCNE2*, *KCNJ2*, *KCNA5*, *KCNH2*, *SCN5A*, *SCN3B*, *NPPA* and *NUP155* have been identified. In recent years, using genome-wide association study

(GWAS), deep sequencing and cis-eQTL mapping, more genetic loci have been revealed for non-familial or common AF, including 1q24, 4q25, 7q31, 9q22, 10q22, 14q23, 15q24, 16q22, and 10p11-q21 (9-11). Notably, variants of five transcription factors mentioned above may play important roles in the pathogenesis of AF. In this review, we will focus on the potential role of transcription factors those identified by GWAS in AF.

## Paired-like homeodomain 2 (*PITX2*)

The association between variants (rs2200733 and rs10033464) on 4q25 and AF was first identified by GWAS enrolled three populations of European descent and a Chinese at 2007 (12). Later, the association was verified in Italian population, Polish population and Chinese (13-15). Clinical studies showed that rs10033464 affected the response to antiarrhythmic drug (AAD) in AF patients, while rs2200733 were supposed to be an independent predictor of AF recurrence after direct current cardioversion

(DCCV). Furthermore, those AF risk variations on 4q25 were associated with increased risk of both early and late AF recurrence after catheter ablation (16-19). Though the expression of paired-like homeodomain 2 (*PITX2*) in human adult left atrial appendages has been reported not associated with the AF risk SNPs on chromosome 4q25 (20), *PITX2* may participate in the mechanism of AF, regarding that *PITX2* is the nearest gene which lies approximately 150,000 base pairs downstream the AF associated variants on 4q25 (21).

*PITX2*, a member of the paired-like homeodomain transcription factor family, encodes three protein isoforms: *PITX2a*, *b*, *c*. Studies showed that *Pitx2* mediated asymmetric left-right signaling in vertebrate situs-specific morphogenesis, especially L/R atrial identity and asymmetrical ventricular remodeling (22-25). *PITX2c* expresses not only in the left atrium and pulmonary vein of embryonic and postnatal mice, but also in rare left atrial myocardial cells in left atrium of 1-year-old mice (24). And in heart of adult human or mouse, the expression level of *PITX2c* in left atrium is about 100-fold higher than in right atrium or in ventricles (26). Specific *Pitx2* knockout mice survived with obvious congenital malformations, conduction system abnormalities, and pulmonary myocardial defects (25). Although the cardiac function and morphology were normal, the action potential was shortened and ectopic automaticity was promoted in the left atrium cardiomyocytes of heterozygous *Pitx2c*-deficient (*Pitx2c*<sup>+/-</sup>) mouse (26).

Whole-genome expression array observed that amounts of genes that were affected by the expression of *PITX2c* might explain the molecular mechanism for abnormal electrical activity and susceptibility to AF in *PITX2c*<sup>+/-</sup> mouse (26). Sinoatrial node (SAN) specific genes *Shox2*, *Tbx3* and *Hcn4*, were up-regulated in the *PITX2* null-mutant embryos (27). *PITX2c* can bind and inhibit the expression of *Shox2*, which plays an essential role in sinoatrial and pacemaker development. *Shox2*, a homeodomain transcription factor, regulates the SAN genetic program through the repression of *Nkx2.5* and *Tbx3* (27-29). *Tbx3*, a member of T-box transcription factors, can influence the specification and formation of the SAN, and the development of left atria as well (28,30,31). Hyperpolarization-activated, cyclic nucleotide-gated 4 (*Hcn4*), a pacemaker channel gene, maintains a stable cardiac rhythm by preventing sinus pauses and has no contribution to the heart rate acceleration (27,32,33). Furthermore, studies showed that *PITX2c* also down-regulated the expression of *Nppa* and *Kcnq1*.

*NPPA* encodes the atrial natriuretic peptide hormone that regulates intravascular volume, and *KCNQ1* encodes potassium channel. Variants in both *NPPA* and *KCNQ1* can cause I(Ks) “gain-of-function” and atrial AP shortening, and result in calcium current change, which known as a common pathogenesis of familial AF (27,34-37). Other target genes of *Pitx2*, include channel and calcium handling genes, and genes that stabilize the intercalated disc in postnatal atrium (38). And a latest integrated genomic analysis discovered that two microRNAs, miR-17-92 and miR-106b-25, were up-regulated by *Pitx2*. The transcription of these microRNAs can repress *Shox2* and *Tbx3*, and play roles in the abnormal electrical activity (39).

### Paired-related homeobox gene 1 (*PRRX1*)

The association between rs3903239 in paired-related homeobox gene 1 (*PRRX1*) on 1q24 and AF was reported in a GWAS study which contained a large number of Europeans and Japanese (40). A latest rare variant joint analysis also found that damaging variants within the *PRRX1* region remained significantly associated with AF (P value =0.01) after Bonferroni correction (41). Both studies highlighted that *PRRX1* may affect the susceptibility to AF.

*PRRX1* encodes a homeodomain transcription factor, which localized in the nucleus and highly expressed in the developing heart (especially the conducting system). It's first observed in the developing chick cardiovascular system, including epicardium, valve, endocardial cushion and the wall of the large arteries and veins (42). Instead of directly interacting with deoxyribonucleic acid (DNA) in its homeodomain, *Prrx1* plays its function by binding the muscle creatine kinase enhancer (43,44). The interaction between *Prrx1* and MADS-domain transcription factors was suggested to influence smooth muscle structural proteins and pulmonary vasculature dysgenesis was observed in the *Prrx1* knockout fetal mouse (43-48). According to highly expression of *PRRX* genes in the developing vascular system, *PRRX1* and *PRRX2* may play important roles in the differentiation of vascular smooth muscle cells (49). Abnormalities of great vessel were observed in double mutants' knockout mouse too (50). A normal heartbeat is initiated in the SAN or pacemaker region, while abnormal electrical activity originated in pulmonary veins can serve to trigger and maintain AF in many pathological conditions (51). These abnormal developments of pulmonary vasculature may offer pulmonary veins the morphological substrate involved in AF. A case-control study has revealed that

an anatomic PV variant, left common ostium (LCO) is associated with the development of AF with OR of 2.1 (P value =0.004) (52). The re-entrant PV tachycardia is also suggested to be a mechanism underlying the initiation of paroxysmal AF (53). Additionally, the distribution and structure of myocardium in the pulmonary veins can also influence the radiofrequency ablation of AF (54).

### Zinc finger homeobox 3 (ZFHX3)

The variation rs7193343 in *ZFHX3* on chromosome 16q22 was first reported to be associated significantly with AF in GWAS [OR of 1.21 (P=1.4×10<sup>-10</sup>)] (55). And this association was replicated in the Polish population (14). Two SNPs (rs2106261 and rs6499600) in *ZFHX3* are strongly associated with AF risk, while another one (rs16971436) is borderline significant in a Chinese Han populations (56). And significant association of SNP rs2106261 with AF was identified in another Chinese Han population (57). Moreover, the polymorphism in *ZFHX3* magnifies the AF risk in HF patients (58).

*ZFHX3* encodes a cardiac transcription factor containing multiple homeodomains and zinc finger motifs. Two missense mutations in *ZFHX3* exon were identified and in silico analysis showed that these mutations resulted in damage of the ZFHX3 protein structure (59). ZFHX3 interacts with the terminal end of protein inhibitor of activated STAT 3 (*PIAS3*), which is a specific inhibitor of signal transducer and activator of transcription 3 (STAT3) through binding to activated tyrosine-phosphorylated STAT3 dimers and subsequently preventing DNA binding to the complex (60,61). STATs were proved to mediate the inflammatory process as the major downstream mediators of many different inflammatory signaling pathways in a pacing-induced AF porcine model. Small GTPase Rac1, a molecular target of statin, mediating the activation of STAT3 by angiotensin II, and JAK/STAT pathways, was activated in this animal model (62). As an independent risk of AF, inflammation play roles in the pathophysiological mechanisms of the initiation and maintenance of AF (63). So this activated angiotensin II/Rac1/STAT signaling was suggested to contribute to electrical and structural remodeling and inflammatory changes in pacing-induced AF model (62). In tachypaced HL-1 cells, the expression of ZFHX3 and PIAS3 decreased, while activated STAT3 up-regulated. Knockdown of ZFHX3 together with PIAS3 activated pacing-induced STAT3 signaling more effectively than knockdown ZFHX3 alone. On the contrary,

overexpression of ZFHX3 reversed the above effect (64). These data indicated that inhibition of ZFHX3 and activation of STAT3 might contribute to AF. Nuclear localization and SUMOylation are important to ZFHX3, and ZFHX3 is observed cooperating with PML NBs to regulate protein SUMOylation in different biological processes in endothelial cells. Cause SUMOylation serves as a third quality control of misfolded and damaged proteins, which contribute to the pathogenesis of many forms of cardiac disease and heart failure, ZFHX3 may also play roles in AF through mediating the SUMOylation of related proteins (65,66).

### T-box 5 (TBX5)

A large scale of GWAS study with 4,304 cases and 46,508 controls from Iceland of European origin revealed the association between T-box 5 (*TBX5*) on 12q24.1 and AF. SNP rs3825214 variant in *TBX5* is strikingly associated with PR interval, QRS duration and AF (67). Another genetic study replicated the association between *TBX5* and AF in Europeans and Japanese, using multiple approaches containing large-scale genotyping, cis-eQTL mapping and functional validation (68). We also demonstrated that rs3825214 in *TBX5* was associated with lone AF in Chinese Han population (69). Furthermore, *TBX5* indwells in the gene modules associated with AF identified by weighted gene co-expression network analysis of human left atrial tissue (70).

*TBX5* belongs to the evolutionarily conserved T-box family of transcription factors, and may play a role in heart development and specification of limb identity (71). In humans, mutations in *TBX5* can cause Holt-Oram syndrome, which includes congenital heart defects, conduction system abnormalities, and upper limb deformities (72,73). In an atypical Holt-Oram syndrome family, affected patients have mild skeletal deformations and almost none has congenital heart disease, and paroxysmal AF. A novel mutation in *TBX5*, c.373 G>A, is co-segregated with the disease and leads to p.G125R, a gain-of-function protein that can interact with NKX2.5. The mutated *TBX5* enhances the DNA-binding properties of the recombinant and activates *Nppa* and *Cx40* promoters. This activation accelerates the AF related genes expression such as *Nppa*, *Cx40*, *Kcnj2*, and *Tbx3* (74). *Tbx5*<sup>-/-</sup> mice can't survive before birth because of failure of heart tube looping and an under-developed caudal part. The expression of *Nppa* and *Cx40* reduced in heterozygous *Tbx5* knockout mice, while up-regulated and resulted in spontaneous beating phenotype

when *Tbx5* was overexpressed in P19C16 embryonic carcinoma cells (75-77). Furthermore, TBX5 can also interact with TBX3, which controls the SAN gene program, induces pacemaker activity and changes ectopic automaticity in atrial myocardium (30,74).

### NK2 homeobox 5 (NKX2.5)

In a three-generation family with inherited cardiac anomalies, the mutation c.768T>A in NK2 homeobox 5 (*NKX2.5*) on 5q34 was identified associated with atrial septal defect and AF (78). Another *NKX2.5* loss-of-function mutation, p.F145S, was identified in AF family, whose inheritance pattern was autosomal dominant with complete penetrance (79). More mutations, such as p.E21Q, p.T180A, p.N19D and p.F186S were identified and expand the spectrum of *NKX2.5* mutations linked to AF (80,81).

*NKX2.5*, a homeobox-containing transcription factor, continuously expresses in heart from development to maturity, and plays its function in the formation and development of heart. Mutations in *NKX2.5* cause a variety of heart malformation diseases: atrioventricular (AV) conduction abnormalities, atrial septal defects, high degree AV block and tetralogy of Fallot (82,83). Functional analysis associated the mutant proteins with significantly reduced transcriptional activity of *NKX2.5* by directly inhibiting its transcription or affecting its nuclear distribution or DNA-binding ability (84). A meta-analysis of GWAS revealed the association between the genetic variations in *NKX2.5* and PR interval (85). Another study enrolled 7,575 individuals (mean age 46 years, 54% women) who underwent routine 12-lead electrocardiography found that variations of *NKX2.5* were associated with the PR interval in the general population. PR interval reflects atrial and AV nodal conduction and individuals with prolonged PR interval have a higher risk of future AF and cardiac sudden death, so *NKX2.5* may affect the disturbances of PR interval and contribute to AF (86).

In transgenic mice that carry a loss of function allele (I183P) for *NKX2.5*, PR prolongation was observed as early as 2 weeks and quickly developed into complete AV block at 4 weeks. Meanwhile, the expression of two gap junctional proteins: *Cx50* and *Cx43* dramatically decreased. These *Nkx2.5* mutated mice all got congenitally structurally normal hearts, yet displayed progressive AV conduction defects and HF (87). Other studies showed that *Nkx2.5* might reduce the genes which were potentially sufficient to provide automaticity in the pulmonary myocardium. And

*Cx40*-negative, *Hcn4*-positive phenotype in the pulmonary myocardium caused by variation of *Nkx2.5* could be an important trigger of AF (88). Furthermore, *NKX2.5* controls *PITX2* expression in inchoate cardiac lateral plate mesoderm instead of pulmonary myocardium, via direct binding to the consensus DNA-binding site within the asymmetry enhancer element of *PITX2*. Considering the role of *PITX2* mentioned before, they may work together to influence the cardiac development and susceptibility substrate of AF (89).

In summary, genetic variations may influence the function of transcription factors and affect the ion channels, development of cardiac conduct system or myocardium fibrosis, and play important roles in the pathogenesis of AF. Identification of the exact targets which are regulated by AF-related transcription factors may lead to potential new treatments to AF.

### Acknowledgements

**Funding:** This work was supported by grants from the National Basic Research Program of China (973 Program: 2013CB531103), the National Natural Science Foundation of China (No. 81270163), and the Program for New Century Excellent Talents at the University of China (NCET-11-0181).

**Disclosure:** The authors declare no conflict of interest.

### References

1. Ferguson C, Inglis SC, Newton PJ, et al. Atrial fibrillation: stroke prevention in focus. *Aust Crit Care* 2014;27:92-8.
2. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *J Am Coll Cardiol* 2011;57:e101-98.
3. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. *J Epidemiol* 2008;18:209-16.
4. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. *J Am Coll Cardiol* 2008;52:865-8.
5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in

- incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119-25.
6. Schoonderwoerd BA, Smit MD, Pen L, et al. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. *Europace* 2008;10:668-73.
  7. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994;271:840-4.
  8. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. *JAMA* 2010;304:2263-9.
  9. Tsai CT, Lai LP, Hwang JJ, et al. Molecular genetics of atrial fibrillation. *J Am Coll Cardiol* 2008;52:241-50.
  10. Hong K, Xiong Q. Genetic basis of atrial fibrillation. *Curr Opin Cardiol* 2014;29:220-6.
  11. Lubitz SA, Ellinor PT. Personalized medicine and atrial fibrillation: will it ever happen? *BMC Med* 2012;10:155.
  12. Gudbjartsson DF, Arnar DO, Helgadóttir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature* 2007;448:353-7.
  13. Viviani Anselmi C, Novelli V, Roncarati R, et al. Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population. *Heart* 2008;94:1394-6.
  14. Kiliszek M, Franaszczyk M, Kozluk E, et al. Association between variants on chromosome 4q25, 16q22 and 1q21 and atrial fibrillation in the Polish population. *PLoS One* 2011;6:e21790.
  15. Shi L, Li C, Wang C, et al. Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. *Hum Genet* 2009;126:843-9.
  16. Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. *J Am Coll Cardiol* 2012;60:539-45.
  17. Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. *Heart Rhythm* 2013;10:849-55.
  18. Husser D, Adams V, Piorkowski C, et al. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. *J Am Coll Cardiol* 2010;55:747-53.
  19. Benjamin Shoemaker M, Muhammad R, Parvez B, et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. *Heart Rhythm* 2013;10:394-400.
  20. Gore-Panter SR, Hsu J, Hanna P, et al. Atrial Fibrillation associated chromosome 4q25 variants are not associated with PITX2c expression in human adult left atrial appendages. *PLoS One* 2014;9:e86245.
  21. Mahida S, Ellinor PT. New advances in the genetic basis of atrial fibrillation. *J Cardiovasc Electrophysiol* 2012;23:1400-6.
  22. Logan M, Pagán-Westphal SM, Smith DM, et al. The transcription factor PITX2 mediates situs-specific morphogenesis in response to left-right asymmetric signals. *Cell* 1998;94:307-17.
  23. Piedra ME, Icardo JM, Albajar M, et al. PITX2 participates in the late phase of the pathway controlling left-right asymmetry. *Cell* 1998;94:319-24.
  24. Campione M, Steinbeisser H, Schweickert A, et al. The homeobox gene PITX2: mediator of asymmetric left-right signaling in vertebrate heart and gut looping. *Development* 1999;126:1225-34.
  25. Tessari A, Pietrobon M, Notte A, et al. Myocardial PITX2 differentially regulates the left atrial identity and ventricular asymmetric remodeling programs. *Circ Res* 2008;102:813-22.
  26. Kirchhof P, Kahr PC, Kaese S, et al. PITX2c is expressed in the adult left atrium, and reducing PITX2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. *Circ Cardiovasc Genet* 2011;4:123-33.
  27. Wang J, Klysiak E, Sood S, et al. PITX2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. *Proc Natl Acad Sci U S A* 2010;107:9753-8.
  28. Espinoza-Lewis RA, Yu L, He F, et al. Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2.5. *Dev Biol* 2009;327:376-85.
  29. Blaschke RJ, Hahurij ND, Kuijper S, et al. Targeted mutation reveals essential functions of the homeodomain transcription factor Shox2 in sinoatrial and pacemaker development. *Circulation* 2007;115:1830-8.
  30. Hoogaars WM, Engel A, Brons JF, et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. *Genes Dev* 2007;21:1098-112.
  31. Wiese C, Grieskamp T, Airik R, et al. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. *Circ Res* 2009;104:388-97.
  32. Harzheim D, Pfeiffer KH, Fabritz L, et al. Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. *EMBO J* 2008;27:692-703.
  33. Herrmann S, Stieber J, Stöckl G, et al. HCN4 provides a 'depolarization reserve' and is not required for heart rate acceleration in mice. *EMBO J* 2007;26:4423-32.
  34. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. *N Engl J Med* 2008;359:158-65.
  35. Ganga M, Espinoza HM, Cox CJ, et al. PITX2 isoform-

- specific regulation of atrial natriuretic factor expression: synergism and repression with Nkx2.5. *J Biol Chem* 2003;278:22437-45.
36. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. *Science* 2003;299:251-4.
  37. Abraham RL, Yang T, Blair M, et al. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. *J Mol Cell Cardiol* 2010;48:181-90.
  38. Tao Y, Zhang M, Li L, et al. PITX2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. *Circ Cardiovasc Genet* 2014;7:23-32.
  39. Wang J, Bai Y, Li N, et al. PITX2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial fibrillation. *Proc Natl Acad Sci U S A* 2014;111:9181-6.
  40. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet* 2012;44:670-5.
  41. Lin H, Sinner MF, Brody JA, et al. Targeted sequencing in candidate genes for atrial fibrillation: the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study. *Heart Rhythm* 2014;11:452-7.
  42. Bergwerff M, Gittenberger-de Groot AC, DeRuiter MC, Patterns of paired-related homeobox genes PRX1 and PRX2 suggest involvement in matrix modulation in the developing chick vascular system. *Dev Dyn* 1998;213:59-70.
  43. Cserjesi P, Lilly B, Bryson L, et al. MHox: a mesodermally restricted homeodomain protein that binds an essential site in the muscle creatine kinase enhancer. *Development* 1992;115:1087-101.
  44. Grueneberg DA, Natesan S, Alexandre C, et al. Human and Drosophila homeodomain proteins that enhance the DNA-binding activity of serum response factor. *Science* 1992;257:1089-95.
  45. Duprey P, Lesens C. Control of skeletal muscle-specific transcription: involvement of paired homeodomain and MADS domain transcription factors. *Int J Dev Biol* 1994;38:591-604.
  46. Hautmann MB, Thompson MM, Swartz EA, et al. Angiotensin II-induced stimulation of smooth muscle alpha-actin expression by serum response factor and the homeodomain transcription factor MHox. *Circ Res* 1997;81:600-10.
  47. Olson EN, Perry M, Schulz RA. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. *Dev Biol* 1995;172:2-14.
  48. Ihida-Stansbury K, McKean DM, Gebb SA, et al. Paired-related homeobox gene Prx1 is required for pulmonary vascular development. *Circ Res* 2004;94:1507-14.
  49. Leussink B, Brouwer A, el Khattabi M, et al. Expression patterns of the paired-related homeobox genes MHox/Prx1 and S8/Prx2 suggest roles in development of the heart and the forebrain. *Mech Dev* 1995;52:51-64.
  50. Bergwerff M, Gittenberger-de Groot AC, Wisse LJ, et al. Loss of function of the Prx1 and Prx2 homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. *Virchows Arch* 2000;436:12-9.
  51. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;339:659-66.
  52. Bittner A, Mönnig G, Vagt AJ, et al. Pulmonary vein variants predispose to atrial fibrillation: a case-control study using multislice contrast-enhanced computed tomography. *Europace* 2011;13:1394-400.
  53. Po SS, Li Y, Tang D, et al. Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. *J Am Coll Cardiol* 2005;45:1871-7.
  54. Weiss C, Gocht A, Willems S, et al. Impact of the distribution and structure of myocardium in the pulmonary veins for radiofrequency ablation of atrial fibrillation. *Pacing Clin Electrophysiol* 2002;25:1352-6.
  55. Gudbjartsson DE, Holm H, Gretarsdottir S, et al. A sequence variant in ZFX3 on 16q22 associates with atrial fibrillation and ischemic stroke. *Nat Genet* 2009;41:876-8.
  56. Liu Y, Ni B, Lin Y, et al. Genetic polymorphisms in ZFX3 are associated with atrial fibrillation in a Chinese Han population. *PLoS One* 2014;9:e101318.
  57. Li C, Wang F, Yang Y, et al. Significant association of SNP rs2106261 in the ZFX3 gene with atrial fibrillation in a Chinese Han GeneID population. *Hum Genet* 2011;129:239-46.
  58. Smith JG, Melander O, Sjögren M, et al. Genetic polymorphisms confer risk of atrial fibrillation in patients with heart failure: a population-based study. *Eur J Heart Fail* 2013;15:250-7.
  59. Tsai CT, Hsieh CS, Chang SN, et al. Next-generation sequencing of nine atrial fibrillation candidate genes identified novel de novo mutations in patients with extreme trait of atrial fibrillation. *J Med Genet* 2015;52:28-36.
  60. Nojiri S, Joh T, Miura Y, et al. ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. *Biochem Biophys Res Commun* 2004;314:97-103.
  61. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. *Science* 1997;278:1803-5.
  62. Tsai CT, Lin JL, Lai LP, et al. Membrane translocation of small GTPase Rac1 and activation of STAT1 and STAT3 in pacing-induced sustained atrial fibrillation. *Heart Rhythm*

- 2008;5:1285-93.
63. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation* 2003;108:3006-10.
  64. Jiang Q, Ni B, Shi J, et al. Down-regulation of ATBF1 activates STAT3 signaling via PIAS3 in pacing-induced HL-1 atrial myocytes. *Biochem Biophys Res Commun* 2014;449:278-83.
  65. Sun X, Li J, Dong FN, et al. Characterization of nuclear localization and SUMOylation of the ATBF1 transcription factor in epithelial cells. *PLoS One* 2014;9:e92746.
  66. Maejima Y, Sadoshima J. SUMOylation: a novel protein quality control modifier in the heart. *Circ Res* 2014;115:686-9.
  67. Holm H, Gudbjartsson DF, Arnar DO, et al. Several common variants modulate heart rate, PR interval and QRS duration. *Nat Genet* 2010;42:117-22.
  68. Sinner MF, Tucker NR, Lunetta KL, et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. *Circulation* 2014;130:1225-35.
  69. Zang X, Zhang S, Xia Y, et al. SNP rs3825214 in TBX5 is associated with lone atrial fibrillation in Chinese Han population. *PLoS One* 2013;8:e64966.
  70. Tan N, Chung MK, Smith JD, et al. Weighted gene coexpression network analysis of human left atrial tissue identifies gene modules associated with atrial fibrillation. *Circ Cardiovasc Genet* 2013;6:362-71.
  71. Naiche LA, Harrelson Z, Kelly RG, et al. T-box genes in vertebrate development. *Annu Rev Genet* 2005;39:219-39.
  72. Li QY, Newbury-Ecob RA, Terrett JA, et al. Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. *Nat Genet* 1997;15:21-9.
  73. Boogerd CJ, Dooijes D, Ilgun A, et al. Functional analysis of novel TBX5 T-box mutations associated with Holt-Oram syndrome. *Cardiovasc Res* 2010;88:130-9.
  74. Postma AV, van de Meerakker JB, Mathijssen IB, et al. A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. *Circ Res* 2008;102:1433-42.
  75. Hiroi Y, Kudoh S, Monzen K, et al. Tbx5 associates with Nkx2.5 and synergistically promotes cardiomyocyte differentiation. *Nat Genet* 2001;28:276-80.
  76. Fijnvandraat AC, Lekanne Deprez RH, Christoffels VM, et al. TBX5 overexpression stimulates differentiation of chamber myocardium in P19C16 embryonic carcinoma cells. *J Muscle Res Cell Motil* 2003;24:211-8.
  77. Bruneau BG, Nemer G, Schmitt JP, et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. *Cell* 2001;106:709-21.
  78. Gutierrez-Roelens I, De Roy L, Ovaert C, et al. A novel CSX/NKX2.5 mutation causes autosomal-dominant AV block: are atrial fibrillation and syncopes part of the phenotype? *Eur J Hum Genet* 2006;14:1313-6.
  79. Huang RT, Xue S, Xu YJ, et al. A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. *Int J Mol Med* 2013;31:1119-26.
  80. Yu H, Xu JH, Song HM, et al. Mutational spectrum of the NKX2.5 gene in patients with lone atrial fibrillation. *Int J Med Sci* 2014;11:554-63.
  81. Xie WH, Chang C, Xu YJ, et al. Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. *Clinics (Sao Paulo)* 2013;68:777-84.
  82. Jay PY, Harris BS, Buerger A, et al. Function follows form: cardiac conduction system defects in Nkx2.5 mutation. *Anat Rec A Discov Mol Cell Evol Biol* 2004;280:966-72.
  83. Ouyang P, Saarel E, Bai Y, et al. A de novo mutation in NKX2.5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death. *Clin Chim Acta* 2011;412:170-5.
  84. Xie WH, Chang C, Xu YJ, et al. Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. *Clinics (Sao Paulo)* 2013;68:777-84.
  85. Pfeufer A, van Noord C, Marcianti KD, et al. Genome-wide association study of PR interval. *Nat Genet* 2010;42:153-9.
  86. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. *JAMA* 2009;301:2571-7.
  87. Kasahara H, Wakimoto H, Liu M, et al. Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. *J Clin Invest* 2001;108:189-201.
  88. Mommersteeg MT, Brown NA, Prall OW, et al. PITX2c and Nkx2.5 are required for the formation and identity of the pulmonary myocardium. *Circ Res* 2007;101:902-9.
  89. Shiratori H, Sakuma R, Watanabe M, et al. Two-step regulation of left-right asymmetric expression of PITX2: initiation by nodal signaling and maintenance by Nkx2. *Mol Cell* 2001;7:137-49.

**Cite this article as:** Zhou M, Liao Y, Tu X. The role of transcription factors in atrial fibrillation. *J Thorac Dis* 2015;7(2):152-158. doi: 10.3978/j.issn.2072-1439.2015.01.21